SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Changes Corporate Name to C3J Therapeutics, Inc.
Appoints David Goesling as Vice President, Finance & Accounting
LOS ANGELES, Nov. 29, 2016 -- C3 Jian, Inc., a private clinical stage biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, announced that the Company has changed its name to C3J Therapeutics, Inc. (“C3J Therapeutics”) effective immediately.
The Company also announced that David Goesling has joined the Company as Vice President, Finance & Accounting.
“We are excited to move forward as C3J Therapeutics, a name that better reflects our focus on developing truly novel therapeutics to reengineer the human microbiome,” commented Todd Patrick, President and CEO. “Furthermore, the addition of David Goesling to our organization significantly expands the relevant industry expertise of our management team. I look forward to leveraging his deep financial and industry expertise as we advance our lead candidate C16G2 through the clinic and explore commercial opportunities in the prevention of dental caries.”
Mr. Goesling has over 30 years of financial and accounting experience with rapidly-growing companies focused on disruptive technologies. Most recently, he was an independent consultant for emerging growth companies in the biotech and technology industries. Prior to that, Mr. Goesling was the CFO of RF Surgical Systems, a venture capital backed medical device company. Prior to joining RF Surgical, he held finance and accounting positions with increasing levels of responsibility in the telecom industry. He began his career in the auditing group at Deloitte & Touche. A Certified Public Accountant, Mr. Goesling holds a BA from the University of Washington and an MBA from the University of Chicago.
About C3J Therapeutics, Inc.
C3J Therapeutics is a clinical stage biotechnology company focused on improving human health through the development and commercialization of targeted, pathogen-specific antimicrobials (STAMPs) that treat and prevent human diseases caused by microbial dysbiosis. A Phase 2 trial of lead candidate C16G2 in the prevention of dental caries is currently underway. The proprietary STAMP platform technology has potential applications to a variety of bacterial infections, and disorders, particularly related to the human microbiome. C3J is based in Los Angeles, California. For more information, please visit http://www.c3jtherapeutics.com.
Contacts: Todd Patrick President & CEO C3J Therapeutics, Inc. Phone: 310.665.2928 x242 Email: [email protected] Investor Relations Stephanie Carrington ICR, Inc. Phone: 646-277-1282 Email: [email protected] Media James Heins ICR, Inc. Phone: 203-682-8251 Email: [email protected]
